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(ILD) experience a high-risk of treatment-related morbidity and 
mortality after any pulmonary radiotherapy. The purpose of this 
study is to systematically review existing literature on SABR-
related mortality and ILD-specific toxicity for patients with co-
existing ES-NSCLC and ILD. 
Methods and Materials: The MEDLINE and Embase databases 
were queried from their respective dates of inception to January 
21, 2016. A total of 3101 records were reviewed. Studies 
involving advanced stage NSCLC, non-SABR radiotherapy 
technique, guidelines, reviews, meta-analyses, 
correspondences, or pediatric populations were excluded. SABR-
related mortality was defined as any death secondary to 
radiation pneumonitis or deaths determined to be directly 
related to radiation therapy by individual study investigators. 
Treatment-related ILD-specific toxicity was defined as Grade ≥ 3 
radiation pneumonitis following SABR. Data on treatment-
related mortality and ILD-specific toxicity for surgical studies 
were also extracted for reference. Mortality and morbidity 
results were summarized with weighted means. 
Results: A total of 13 SABR studies published between 2003 and 
2015 were included in this systematic review. Ten studies were 
retrospective in design, with the others being a mixed 
retrospective/prospective observational study, a Phase I clinical 
trial and a case report. A total of 122 patients were included in 
the reports, with most studies including medically inoperable 
patients. Weighted mean for treatment-related mortality was 
15.6% after SABR in patients with co-existing ES-NSCLC and ILD. 
Treatment-related ILD-specific toxicity occurred in 25.9% of 
SABR patients. An additional 28 surgical studies were reviewed, 
which included a total of 1681 patients. From 1999 to 2015, 
medically operable patients with co-existing ES-NSCLC and ILD 
who underwent surgery experienced treatment-related mortality 
of 2.0% and ILD-specific toxicity of 11.7%. 
Conclusions: A high incidence of treatment-related mortality 
(16%) and ILD-specific toxicity (26%) was observed after SABR for 
patients with co-existing ES-NSCLC and ILD. Many SABR patients 
were medically inoperable, preventing direct comparisons with 
surgical outcomes. Patients should be cautioned about this 
increased risk of toxicity. Future studies should aim to establish 
a specific diagnosis of the type and severity of ILD prior to the 
treatment of any patient with ES-NSCLC and co-existing 
pulmonary comorbidity. 
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Purpose: Sarcopenia, a depletion of a skeletal muscle with or 
without loss of fat mass, has been studied as a prognostic factor 
in several cancers. It has been shown to be associated with 
poorer survival and worse post-operative outcomes independent 
of patients' body weight. However, it has not been used in 
routine clinical evaluation nor has its prognostic significance in 
lung cancer been evaluated. This study examined the value of 
sarcopenia as a prognostic factor in patients with locally 
advanced non-small cell lung cancers treated with radical 
radiation and chemotherapy.  
Methods and Materials: This study included all patients with 
Stage III non-small cell lung cancer treated with radical radiation 
and chemotherapy at a regional cancer centre using the Glans 
Look database between 2006 and 2012. Body composition 
analysis of planning or pre-treatment diagnostic CT scans was 
performed using Eclipse (Varian, Palo Alto, CA) per a previously 
validated and reported technique. Total skeletal muscle area 
was calculated on a single axial abdominal CT slice at the level 
of L3 vertebral body and adjusted for stature. Patients were 
classified as sarcopenic or nonsarcopenic using validated sex-
specific cut-offs of L3 skeletal muscle index (52.4 cm2/m2 for 
males and 38.5 cm2/m2 for females). Kaplan-Meier survival 
estimates and Cox proportional-hazard models were used to 
determine the impact of sarcopenia on overall survival. 
Results: A total of 106 patients (53% males, 47% females), with 
mean age 65 years (SD = 8.7) were analyzed. Mean BMI was 26.3 
kg/m2 (SD = 6.7 kg/m2). Only one patient was underweight (BMI 
< 18.5), 40% patients had normal weight and 60% of patients were 
either overweight or obese. Overall, 38.7% patients were 
sarcopenic. The prevalence of sarcopenia was 56% among 
patients with normal weight and 27% among overweight or obese 
patients. Sarcopenia was identified as an independent predictor 
of overall survival on multivariate analysis (hazard ratio 1.71; 
95% CI 1.09 – 2.72, p = 0.019). Other significant predictors for 
worse overall survival included age over 65 years and absence of 
concurrent chemotherapy. Median survival in sarcopenic patients 
was 21 months (95% CI 13 – 28 months) compared with 31 months 
(95% CI 20 – 39 months) in nonsarcopenic patients.  
Conclusions: Sarcopenia is independently associated with 
inferior survival in patients with locally advanced non-small cell 
lung cancers treated with chemoradiotherapy. It can be routinely 
assessed in clinical practice using radiation planning software. 
Sarcopenia as independent predictor for survival and toxicity 
outcomes should be included in larger prospective clinical 
studies.  
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Purpose: The management of small cell lung cancer (SCLC) with 
radiotherapy (RT) is variable, with many treatment regimens 
described in the literature. We created a survey to assess 
patterns of practice and clinical decision making in the 
management of SCLC by Canadian radiation oncologists (ROs).  
Methods and Materials: A 35-item survey was e-mailed to 
Canadian ROs. Questions investigated the role of RT, dose/timing 
of RT, target delineation, and use of prophylactic cranial 
irradiation (PCI) in limited stage (LS) and extensive stage (ES) 
SCLC.  
Results: Fifty-two eligible ROs responded. For LS-SCLC, staging 
(98%) and simulation/dosimetric (96%) CT imaging were key 
determinants of RT suitability. The two most common 
dose/fractionation schedules were 40-45 Gy/15 once daily (QD) 
(40%) and 45 Gy/30 twice daily (33%). Elective nodal irradiation 
was performed by 31% of ROs. Preferred management of clinical 
T1/2aN0 SCLC favored primary chemoradiotherapy (64%). For ES-
SCLC, consolidative thoracic RT was frequently offered (88%), 
with a preferred dose/fractionation of 30 Gy/10 QD (70%). 
Twenty-three ROs (44%) would not offer extrathoracic 
consolidative RT. After response to initial treatment, PCI was 
generally offered in both LS- (100%) and ES- (98%) SCLC. 
Performance status, baseline cognition, and pre-PCI brain 
imaging were important clinical factors assessed prior to offering 
PCI.  
Conclusions:  There are both variations and alignment in 
practice in the management of SCLC by Canadian ROs. Future 
clinical trials and national treatment guidelines may reduce 
variability in treating early-stage disease, optimizing 
dose/targeting in LS-SCLC, and defining suitability for both PCI 
and consolidative RT. 
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Purpose: Prophylactic cranial irradiation (PCI) has been shown 
to provide a survival benefit and decrease occurrence of brain 
metastases in patients with small cell lung cancer (SCLC). 
